Drugs (variants) and methods for restoring microflora

Abstract

The invention relates to microbiology and medicine and can be used to prevent and treat diseases and conditions associated with disruption of normal (autochthonous) microflora (microbiota) in humans or animals. In particular, a solution for recovery or creation of the subject's microflora comprising an active component containing microorganisms isolated from the microflora of the subject or the donor, wherein the active component can be enriched with bacteriophages of said microflora and/or additional microorganisms of the microflora cultivated on a nutrient medium, while the additional microorganisms of the microflora include microorganisms of the microflora that are yet nonculturable in the absence of the host organism, is proposed. Also provided are a pharmaceutical dosage form comprising the above solution and methods for prevention or treatment of diseases and/or conditions associated with and/or accompanied by a disorder or lack of the subject's own microflora, comprising administering the solution or pharmaceutical dosage form.

Claims

1. A pharmaceutical dosage form for restoration or creation of microbiota of a subject, comprising (i) an active component comprising bacteria and bacteriophages isolated from microbiota of the subject or microbiota of a donor selected from the subject's mother, subject's sisters and brothers of the whole blood, and other relatives on the maternal side, and (ii) a pharmaceutically acceptable excipient.

2. The pharmaceutical dosage form according to claim 1, wherein the dosage form comprises at least one bacterium selected from bacteria belonging to: Actinomycetales, Bacteroidales, Flavobacteriales, Bacillales, Lactobacillales, Clostridiales, Erysipelotrichales, Selenomonadales, Fusobacteriales, Neisseriales, Campylobacterales, and Pasteurellales.

3. The pharmaceutical dosage form according to claim 1, wherein the dosage form comprises at least one bacterium selected from bacteria belonging to: Aerococcaceae, Burkholderiaceae, Carnobacteriaceae, Coriobacteriaceae, Erysipelotrichaceae, Eubacteriaceae, Lachnospiraceae, Leptotrichiaceae, Micrococcaceae, Peptostreptococcaceae, Porphyromonadaceae, Prevotellaceae, Pseudomonadaceae, Ruminococcaceae, Streptococcaceae, and Veillonellaceae.

4. The pharmaceutical dosage form according to claim 1, wherein the dosage form comprises Archaea and/or fungi isolated from microbiota of the subject or microbiota of a donor selected from the subject's mother, subject's sisters and brothers of the whole blood, and other relatives on the maternal side.

5. A pharmaceutical dosage form for restoration or creation of microbiota of a subject, comprising (i) an active component comprising bacteriophages isolated from microbiota of the subject, or microbiota of a donor selected from the subject's mother, subject's sisters and brothers of the whole blood, and other relatives on the maternal side, and (ii) a pharmaceutically acceptable excipient.

6. The pharmaceutical dosage form according to claim 5, wherein the active component comprises bacteriophages isolated from microbiota of a donor selected from the subject's sisters and brothers of the whole blood, and other relatives on the maternal side.

7. The pharmaceutical dosage form according to claim 1, wherein the ratio of bacteriophages to the bacteria is 1000:1 to 100:1.

8. The pharmaceutical dosage form according to claim 1, wherein the active component comprises bacteria and/or bacteriophages cultivated on a nutrient medium.

9. The pharmaceutical dosage form according to claim 1, wherein the pharmaceutically acceptable excipient is selected from isotonic sodium chloride, activated carbon, silica, chalk, sugar, lactose, gelatin, starch, polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), cellulose, methyl cellulose (MC), hydroxypropylmethyl cellulose (CMO), carboxymethyl cellulose (CMC), and sodium carboxymethylcellulose (Na-CMC).

10. The pharmaceutical dosage form according to claim 1, wherein the active component is obtained by cultivation of at least a portion of bacteria and/or bacteriophages isolated from microbiota of the subject or microbiota of the donor under aerobic and/or anaerobic conditions.

11. The pharmaceutical dosage form according to claim 10, wherein the active component is obtained by cultivation of 10.sup.9 to 10.sup.12 bacteria per ml.

12. The pharmaceutical dosage form according to claim 1, wherein the active component comprises bacteria and bacteriophages isolated from the microbiota of saliva, mucous membranes, skin, gastrointestinal tract, and/or feces.

13. The pharmaceutical dosage form according to claim 1, wherein the active component is formulated in a form suitable for freezing and long-term storage.

14. The pharmaceutical dosage form according to claim 1, wherein the dosage form further comprises bacteria that enhance the ability of bacteria in the active component to colonize certain areas of the skin or mucosa.

15. The pharmaceutical dosage form according to claim 1, wherein the dosage form is prepared in the form of capsules, tablets, pellets, caplets, powder, aerosol, lyophilizate, gel, suspension cream, emulsion, or suspension in a nutrient medium or other suitable liquid.

16. The pharmaceutical dosage form according to claim 1, wherein the dosage form is formulated in a form selected from the forms suitable for dissolution in the oral cavity, small intestine, stomach, and large intestine.

17. The pharmaceutical dosage form according to claim 1, wherein the dosage form is prepared in a form suitable for buccal or sublingual administration.

18. The pharmaceutical dosage form according to claim 1, wherein the dosage form is prepared in a form suitable for transmucosal administration.

19. The pharmaceutical dosage form according to claim 1, wherein the dosage form is prepared in a form suitable for intravaginal administration.

20. The pharmaceutical dosage form according to claim 1, wherein the active component comprises bacteria and bacteriophages isolated from the microbiota of a donor selected from subject's sisters and brothers of the whole blood and other relatives on the maternal side.

21. The pharmaceutical dosage form of claim 1, wherein the dosage form comprises 10.sup.3 to 10.sup.12 bacteriophages per 1 ml of the dosage form.

22. The pharmaceutical dosage form of claim 6, wherein the dosage form comprises 10.sup.3 to 10.sup.12 bacteriophages per 1 ml of the dosage form.

23. A method for the treatment of a disease in a subject in need thereof, comprising administering to the subject the dosage form according to claim 1, wherein the disease is selected from ulcerative colitis, irritable bowel syndrome, increased intestinal permeability, intestinal permeability syndrome, mucosal candidiasis, bowel dysfunction, flatulence, vaginosis, tumor diseases, Crohn's disease, rheumatoid arthritis, Alzheimer's disease, Parkinson's disease, schizophrenia, depression, autism, bipolar disorder, arrhythmias, cachexia, aging, sudden death syndrome, renal insufficiency, hepatic insufficiency, and glomerulonephritis.

24. A method for creating a normal microbiota in a baby delivered by Caesarean section, comprising administering to the baby the dosage form according to claim 1, wherein the active component of the dosage form comprises bacteria and bacteriophages isolated from the baby's mother's microbiota or the microbiota of a donor selected from the baby's sisters and brothers of the whole blood and other relatives on the maternal side.

25. A method for creating a normal microbiota in a baby delivered by a surrogate mother, comprising administering to the baby the dosage form according to claim 1, wherein the active component of the dosage form comprises bacteria and bacteriophages isolated from the baby's genetic mother's microbiota or the microbiota selected from the baby's sisters and brothers of the whole blood and other relatives on the maternal side.

26. A method for prevention and/or treatment of a tumor disease in a subject in need thereof, comprising administering to the subject the dosage form according to claim 1.

27. A method for treatment of increased intestinal permeability in a subject in need thereof, comprising administering to the subject the dosage form according to claim 1.

28. The method according to claim 23, wherein the active component of the dosage form comprises bacteria and/or bacteriophages cultivated on a nutrient medium and wherein said bacteria and/or bacteriophages are added to the active component 1 hour to 1 day before the administration of the dosage form.

29. The method according to claim 24, wherein the active component of the dosage form comprises bacteria and/or bacteriophages cultivated on a nutrient medium and wherein said bacteria and/or bacteriophages are added to the active component 1 hour to 1 day before the administration of the dosage form.

30. The method according to claim 25, wherein the active component of the dosage form comprises bacteria and/or bacteriophages cultivated on a nutrient medium and wherein said bacteria and/or bacteriophages are added to the active component 1 hour to 1 day before the administration of the dosage form.

31. The method according to claim 26, wherein the active component of the dosage form comprises bacteria and/or bacteriophages cultivated on a nutrient medium and wherein said bacteria and/or bacteriophages are added to the active component 1 hour to 1 day before the administration of the dosage form.

32. The method according to claim 27, wherein the active component of the dosage form comprises bacteria and/or bacteriophages cultivated on a nutrient medium and wherein said bacteria and/or bacteriophages are added to the active component 1 hour to 1 day before the administration of the dosage form.

Description

DETAILED DESCRIPTION OF THE INVENTION

(1) In the present description, the terms “microflora”, “microbiota”, “microbiocenosis” are interchangeable and refer to the totality of various types of microorganisms inhabiting any habitat.

(2) In the present description, the terms “microbe” and “microorganism” are interchangeable and refer to a group of living organisms whose dimensions are, in particular, less than 1 mm. They include, in particular, protozoa, bacteria, viruses, fungi, yeast.

(3) Viruses, in turn, include bacteriophages, which are viruses of bacteria.

(4) Nonculturable or yet nonculturable forms of microorganisms are those forms of microorganisms that, in the absence of the host organism or in response to the influence of unfavorable factors, stop growth on nutrient media, but remain viable, and with improved cultivation conditions, resume their proliferation. In other words, in this case, the microorganisms pass into a nonculturable state, in which they can be for a long time. The term “yet nonculturable” or “previously nonculturable”, referring to microorganisms, means that at the time of preparation of this application the possibility to ensure growth of such microorganisms on a nautrient media in the absence of the host organism is not known (see, for example, Colwell, R., Grimes J. “Nonculturable Microorganisms in the Environment”, ASM Press, 2000. pp. 2-3).

(5) According to one of the aspects of the invention, a solution for recovery or creation of the subject's microflora is provided comprising an active component comprising microorganisms isolated from the subject's own microflora or a microflora of a donor selected from the group comprising his/her mother and/or other relatives on the maternal side and, in addition, a component that enhances the effect of the solution.

(6) According to one of the embodiments, microorganisms are bacteria isolated from material obtained from the subject or a donor, as well as archaea and/or fungi isolated from the subject's own microflora or microflora of a donor selected from the group comprising his/her mother and/or relatives on the maternal side, and additionally, a component that enhances the effect of the solution.

(7) According to one of the embodiments, as an additional component enhancing the effect of the solution, the solution further comprises bacteriophages isolated from material obtained from the subject or a donor.

(8) According to one of the embodiments, the material obtained from the subject or donor can be a material derived from the oral cavity (saliva, scrapings, mucus washings, sputum), other parts of the gastrointestinal tract (GT) (esophagus, stomach, intestines), feces, skin, respiratory tract, genital organs, urethra, conjunctiva, external auditory canal.

(9) According to one of the embodiments, the ratio of bacteria isolated from the genuine microflora to bacteriophages isolated from the genuine microflora in the solution is 1000:1 to 1:1000.

(10) According to one of the embodiments, the ratio of bacteria to bacteriophages in the solution is selected from the following list: 1000:1 to 100:1, 100:1 to 10:1, 10:1 to 1:10; 1:10 to 1:100; 1:100 to 1:1000. According to one of the embodiments, as an additional component enhancing the effect of the solution, the solution further comprises microflora bacteria cultivated on a nutrient medium comprising yet nonculturable forms of microorganisms of the microflora.

(11) According to one of the embodiments, the solution further comprises both bacteriophages isolated from the material obtained from the subject or a donor, and additional microorganisms of microflora cultivated on a nutrient medium, comprising yet nonculturable forms of microorganisms of the microflora.

(12) The additional microorganisms referred to may be cultivated on a nutrient medium in advance and stored prior to addition to the active component under suitable conditions, wherein addition of said additional microorganisms can be performed immediately prior to administration, in particular about 1 hour, about 1 day before administration of the solution.

(13) According to one of the embodiments, the microflora can be a normal microflora of healthy people, including but not limited to, the microflora of the oral cavity (saliva, scrapings, mucus washings, sputum), other parts of the gastrointestinal tract (GT) (esophagus, stomach, intestines), feces, skin, respiratory tract, genital organs, urethra, conjunctiva, external auditory canal. The carrier individual (genuine microflora), sisters and brothers of the whole blood, mother, as well as relatives on the maternal side (mother's sisters and their children, all descendants in the first generation, children of daughters in the second generation, etc.) can all act as donors of microflora, as well as other donors in the absence of the listed (donor microflora). In one of the embodiments, the microflora is sampled from the subject or donor in childhood and adolescence.

(14) In one of the embodiments, the subject is an animal, in particular a mammal, in particular a human of any age, including a child.

(15) The sampling of biological material from the subject or a donor is carried out by standard methods. According to one of the embodiments, the biological material selected from the subject or a donor, for example feces, is mixed in a sterile isotonic sodium chloride solution or other suitable buffer and filtered to remove undigested food particles, after which the microorganisms are precipitated by centrifugation.

(16) According to one of the embodiments, washings from the skin or scrapings from the mucosa are obtained by standard methods, after which a sterile isotonic sodium chloride solution or other suitable buffer is added to the biological material.

(17) According to one of the embodiments, fresh saliva is used, for example, in a volume of 5-10 ml, into which flushing from a cotton swab that is used to collect microbes from the buccal mucosa is added. The washings from swabs are carried out with a sufficient volume of a sterile isotonic sodium chloride solution, for example 1.0 ml. As a result, it is possible to obtain the maximum variety of oral bacteria, which includes cultured and yet nonculturable microbes. Further, the procedure is similar to that used to collect microbes from another material. In particular, the obtained material can be placed in conical tubes, after which rapid precipitation by centrifugation is carried out. To the resulting precipitate, an isotonic sodium chloride solution can be added and individual doses comprising 0.001 to 10.0 ml of the original microbial mixture.

(18) According to one of the embodiments, bacteriophage from the subject or a donor material, after removing bacteria from the material, it is filtered through a filter with a pore size of 0.17-0.25 μm, after which the phages are washed off the filter with a minimum amount of the buffer used or an isotonic sodium chloride solution.

(19) The volume of biological material taken from the subject or a donor is determined depending on the age of the subject or the donor and the location of the material sampling. A person skilled in the art will determine the required volume of material based on the type of biological material, the preparation method of the drug, the pharmaceutical form and the type of administration, as well as other factors.

(20) In this description, the terms “previously sampled”, “previously obtained”, and “previously isolated”, relating to the microflora and/or microorganisms of the present invention, mean in particular that the material, microflora or microorganisms are selected, obtained or isolated from the subject or a donor before the beginning of restoration or creation of microflora in the subject, prevention or treatment of diseases and conditions associated with and/or accompanied by a disorder or lack of the subject's own microflora, before exposure of the subject's organism that can lead to the disorder, damage or destruction of the microflora of the subject, and also before the onset of the development of the disease or condition associated with and/or accompanied by a disorder or lack of the subject's own microflora.

(21) The microflora obtained from the subject or a donor can be used immediately or stored, in particular in a microflora bank.

(22) The microflora or the solution can be stored under a variety of conditions, including, but not limited to, the following: at a temperature of about −70° C. to −80° C., the liquid nitrogen temperature or in the form of a lyophilized dried preparation. According to the embodiments, samples of microflora or the solution can be stored frozen in separate vials for later use.

(23) For storage of samples of the selected microflora, stabilizers can be added to ensure their long-term preservation, which can be controlled (for example, for maximum of once a year) during the storage period by the ability to grow on a nutrient medium specially developed by the authors. According to one of the embodiments, the stabilizers are selected from the group comprising glycerin and other potential (commercial) stabilizers.

(24) According to one of the embodiments, the solution is obtained by sampling biological material (including saliva, sputum, faeces) from healthy subjects and/or donors (e.g., relatives on the maternal side), removing non-bacterial impurities from it, storing the resulting material as separate samples during the life of the subject or a donor. The number of bacteria in the samples can be from 10.sup.1-10.sup.10, for example, 10.sup.1 to 10.sup.3, 10.sup.1 to 10.sup.5, 10.sup.3 to 10.sup.5, 10.sup.5 to 10.sup.7, 10.sup.6 to 10.sup.8, 10.sup.7 to 10.sup.10, 10.sup.3 to 10.sup.7, and the amount of bacteriophages in the samples can be from 10.sup.1-10.sup.12 in 1 ml/sample, for example, 10.sup.1 to 10.sup.3, 10.sup.1 to 10.sup.5, 10.sup.3 to 10.sup.5, 10.sup.5 to 10.sup.7, 10.sup.6 to 10.sup.8, 10.sup.7 to 10.sup.10, 10.sup.3 to 10.sup.12 in 1 ml/sample.

(25) According to one of the embodiments, the solution can be used for oral, enteral, local, buccal, sublingual, duodenal, transmucosal, intravaginal, and rectal administration, in particular in the form of enemas.

(26) According to one of the embodiments, the solution according to the described aspects, containing strains of autochthonous microflora of healthy people, allows to restore the damaged bacteriobiocenosis in the case of disorders of its own microflora associated with a disease, administration of antibiotic, age, etc.

(27) Administration to a subject of the solution containing microorganisms isolated from the autochthonous microflora of the subject or the microflora of a donor enriched with bacteriophages isolated from the biological material collected from the subject and/or the donor and/or additional microorganisms of the microflora cultivated on a nutrient medium containing microflora of yet nonculturable microorganisms, allows you to quickly and efficiently restore the microflora of the subject's body by means of microorganisms and bacteriophages inherent in this particular subject.

(28) Enrichment of the solution with additional microorganisms of the microflora cultivated on a nutrient medium, including yet nonculturable microorganisms of the microflora, allows to reach the concentrations of microorganisms in the medium that are as close as possible to the concentrations of microorganisms in the organism of the subject in the healthy state.

(29) According to one of the embodiments, the active component can be obtained by cultivation of at least some part of the microflora, for example, at least 100 bacteria per ml, or a larger amount of up to 10.sup.12 bacteria per ml under aerobic or anaerobic conditions.

(30) According to the exemplary embodiments, the active component can be obtained by cultivation of at least 100 to 1000 bacteria per ml, 1000 to 10,000 bacteria per ml, 10.sup.3 to 10.sup.5 bacteria per ml, 10.sup.5 to 10.sup.7 bacteria per ml, 10.sup.∂to 10.sup.9 bacteria per ml, 10.sup.9 to 10.sup.12 bacteria per ml or more bacteria per ml under aerobic or anaerobic conditions.

(31) According to the exemplary embodiments, the active component may be present in the composition of the solution in any amount that is capable of providing the desired effect according to the described aspects and embodiments, for example in an effective amount. A medical specialist will be able to easily choose an appropriate amount of the active component for the solution according to the present invention, which is necessary to achieve the desired effect.

(32) With age, the number of microorganisms and bacteriophages of microflora may decrease. Accordingly, in one of the embodiments, the microflora of the subject or a donor is sampled from the subject or the donor in childhood or adolescence. Administration of the microflora sampled in childhood and adolescence to the subject can contribute to a more rapid and more effective recovery of the microbiocenosis of the subject's body.

(33) In some cases, it is sufficient to introduce only bacteriophages that are inherent in the subject's body. Bacteriophages are viruses of bacteria, they contribute to their variability and adaptation, and also can cause their death. Possessing high sensitivity, they selectively affect certain types of bacteria, without harming the normal intestinal microflora. Accordingly, bacteriophages can be used to treat and prevent diseases and conditions associated with a disorder of the normal biocenosis of the body.

(34) It is known to use bacteriophages to enhance the therapeutic effect and restore the normal microflora. In the absence of bacteria sensitive to bacteriophage, the duration of their stay in the human body is no longer than 1-3 days. They give few adverse reactions and complications, increase the effectiveness of treatment with various antibacterial drugs, increase immunity. It is known that bacteriophages can be used to treat dysbacteriosis in newborns and children in the first year of life.

(35) However, known drugs for the treatment of microflora disorders using bacteriophages have a number of disadvantages. As far as is known to the authors of the present invention, the available preparations based on bacteriophages are narrowly specific due to the use of specific phages that destroy certain types of bacteria. In addition, the body quickly develops phage-resistant strains, so in this case treatment cannot be prolonged. Also, bacteriophages can cause allergic reactions.

(36) In contrast to the known preparations using bacteriophages, the present invention employs bacteriophages isolated from a material obtained from the subject or a donor on the maternal side. This allows to increase the efficiency of microflora recovery, eliminate allergic reactions and also, in special cases of implementation, provide a complex effect on the organism in which the active components of the composition according to the invention enhance each other's action, in particular, the presence of bacteriophages along with the bacteria of the genuine microflora can help suppress the development of foreign microorganisms and promote restoration of the normal microflora of the subject.

(37) According to the exemplary embodiments, the solution may be a single-component or multi-component, for example, may be presented in the form of a composition or a formulation, including a pharmaceutical composition or a formulation, and a drug, optionally containing at least one pharmaceutically acceptable vehicle and/or excipient.

(38) According to one of the embodiments, a pharmaceutically acceptable vehicle and/or excipient is selected from the group consisting of the following: sodium chloride (for example, as an isotonic solution), activated carbon (e.g., activated carbon powder), silica, chalk (e.g., suspension of chalk particles), sugar, lactose, gelatin, starch, polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), cellulose, methyl cellulose (MC), hydroxypropylmethyl cellulose (CMO), carboxymethyl cellulose (CMC), sodium carboxymethylcellulose (Na—CMC) and other substances conventionally used as pharmaceutically acceptable vehicles and/or excipients.

(39) Pharmaceutical Dosage Forms

(40) According to one of the embodiments, a pharmaceutical dosage form for recovery and/or creation of a microflora of a subject, as well as for the prevention and/or treatment of diseases and/or conditions associated with and/or accompanied by a disorder or lack of the subject's own microflora is provided, comprising a solution according to the described aspect and embodiments, and a pharmaceutically acceptable excipient.

(41) Pharmaceutical dosage forms can be prepared in the form of capsules, tablets, pellets, caplets, powder, water suspension, suspension in a nutrient medium or other suitable liquid, suspensions, emulsions, aerosols, gel, lyophilisate, cream.

(42) Pharmaceutical dosage forms can be prepared in a form intended for oral, enteral, local, buccal, sublingual, duodenal, transmucosal, intravaginal, rectal administration. According to exemplary embodiments of the invention, pharmaceutical dosage forms are proposed prepared in a form suitable for dissolution in the oral cavity, small intestine, stomach, large intestine.

(43) According to embodiments of the invention, dosage forms suitable for buccal or sublingual administration, for transmucosal administration, for example, by means of an endoscope, for intravaginal administration, are proposed.

(44) According to exemplary embodiments, the proposed solution and/or pharmaceutical forms can be used to treat diseases and/or conditions associated with and/or accompanied by a disorder or lack of microflora in the subject are selected from the group consisting of ulcerative colitis, irritable bowel syndrome, intestinal permeability syndrome, mucosal candidiasis, bowel dysfunction, flatulence, vaginosis, tumor diseases; diseases and/or conditions that occur against the background of hormonal disorders, long-term antibiotic therapy, X-ray and chemotherapy, the effects of cytostatics and drugs used in transplantology, as a result of use of antitumor drugs; diseases and/or conditions associated with delivery by Caesarean section and the birth from a surrogate mother in the natural manner.

(45) In yet another aspect, a complex for the prevention and/or treatment of diseases and/or conditions associated with and/or accompanied by a disorder or lack of the subject's own microflora is provided, comprising the solution or at least one pharmaceutical dosage form according to the described aspects and exemplary embodiments, and instructions for administering to the subject.

(46) Pharmaceutical dosage forms (a drug, a preparation) for administration to the subject can be prepared by standard methods.

(47) According to one of the embodiments, for the preparation of an enteric dosage form in the form of enteric-soluble capsules, powder of activated carbon or silica, or a suspension of chalk particles or cellulose particles, or other filler may be added to create a consistent mixture suitable for filling the capsules. According to one of the embodiments, the solution is administered orally with a duration determined by the subject's condition and the type of pathology.

(48) For enteral administration, liquid dosage forms can also be used. Such forms can be prepared by diluting microflora samples with water or another liquid suitable for drinking. The subject receives the drug in the form of drops or a liquid for drinking. The preparation can be enriched with various consistent food additives to give it a gel-like form and/or with flavoring nutritional supplements.

(49) The preparation can also be administered to the intestine rectally, for example, by enemas, or orally, for which the samples are diluted with water or another liquid suitable for such an administration route, and the subject receives the drug in the form of drops or a liquid for drinking.

(50) For the local application of the medicament, for example for application to the skin or mucous membranes, permitted (for example, pharmaceutically acceptable) substances may be added to the microbial material to impart the desired consistency and/or adhesive properties and/or taste and/or color, and/or other cosmetically important and customer-related properties.

(51) Methods for Restoring the Composition of Microflora

(52) According to the invention, methods for recovering the composition of or creating an organism microflora that has been impaired or weakened by diseases and/or conditions associated with and/or accompanied by a disorder or lack of the subject's own microflora is provided, comprising administering the solution or a pharmaceutical dosage form according to any of the described aspects.

(53) According to the exemplary embodiments, diseases and/or conditions associated with and/or accompanied by a disorder or lack of genuine microflora in the subject are selected from the group consisting of ulcerative colitis, irritable bowel syndrome, intestinal permeability syndrome, mucosal candidiasis, bowel dysfunction, flatulence, vaginosis, tumor diseases; diseases and/or conditions that occur against the background of hormonal disorders, long-term antibiotic therapy, X-ray and chemotherapy, the effects of cytostatics and drugs used in transplantology, as a result of use of antitumor drugs; diseases and/or conditions associated with delivery by Caesarean section and the birth from a surrogate mother in the natural manner.

(54) According to the exemplary embodiments, tumor diseases are diseases caused by the transformation of normal cells of organs and tissues into tumor cells prone to uncontrolled proliferation. Such diseases include benign and malignant neoplasms and can be manifested in the form of (including but not limited to) a fibroma, myoma, osteoma, lipoma, cancer, carcinoma, sarcoma, blastoma, lymphoma, leukemia, melanoma, teratoma or glioma of any organ, for example, the organ of the gastrointestinal tract, the urinary system, respiratory system, nervous system, integumentary system, musculoskeletal system, cardiovascular system, hematopoiesis system, and in particular, intestinal tumors, including small intestine, large intestine, straight intestine, dodecadactylon; ventricle, esophagus, liver, pancreas, oral cavity and pharynx, gallbladder, heart, larynx, lung, breast, skin, ovary, prostate, uterus, thyroid, brain and spinal cord.

(55) According to the invention, the proposed method comprises administration of the microorganisms comprising bacteria isolated from a normal genuine microflora of a healthy subject or microflora of a donor from the maternal side. Additionally, bacteriophages of microflora can be used for treatment together with microflora bacteria, and also, before starting the treatment, the preparation can be enriched with genuine bacteria cultivated on a rich nutrient medium under aerobic or anaerobic conditions, after seeding stored samples of the treated subject's microflora or microflora of his/her relatives on maternal side.

(56) According to one of the embodiments, the method for recovering the composition of or creating an organism microflora that has been impaired or weakened by diseases and/or conditions associated with and/or accompanied by a disorder or lack of the subject's own microflora, comprises the following: collection of a sample of the normal microflora of the subject, and/or microflora of the donor selected from the relatives of the subject, for example, relatives on the maternal side; preparation of a solution containing microorganisms isolated from the subject's own microflora and/or that of his/her relatives, for example, relatives on the maternal side, including bacteria isolated from microflora, and/or bacteria together with bacteriophages isolated from microflora and/or only isolated bacteriophages isolated from microflora; affecting the subject, where undesirable disturbance of his/her microflora occurs; administration of an effective amount of the solution prepared over a period of time sufficient to restore normal microflora to the subject.

(57) The regimen of administration of microflora can span from one day to one year, possibly from 1 day to 10 days, from 10 days to 20 days, from 10 days to 30 days, and more.

(58) According to one of the embodiments, a method of prevention and treatment is provided comprising administering the solution or a pharmaceutical form as described above for a period of 1-5 days, with a break for 1-20 days, then a repeated administration for 1-5 days.

(59) In one of the embodiments, a method of prevention and treatment is provided comprising administering the solution or a pharmaceutical form as described above for a period of 5-10 days, with a break for 1-20 days, then a repeated administration for 5-10 days, and then, if necessary, the above cycle is repeated once more.

(60) According to one of the embodiments, the subject's normal microflora is sampled prior to initiating exposure of the subject that may cause a disruption in the composition of the microflora, for example, prior to initiation of antibiotic treatment, or prior to initiation of treatment with other drugs that may cause microflora damage or exposure to radiation; in such cases, as for example, the effect on benign or malignant tumors, samples of microflora are obtained from the subject to whom such treatment is prescribed, which are stored in the corresponding conditions before the end of the damaging effects. Upon termination of the damaging exposure, a preparation containing bacteria isolated from the healthy microflora of the subject is prepared, as described above, to restore the normal microflora of the subject.

(61) Alternatively, it is possible that at the time of the encounter with the specialist, the subject has already been treated with drugs that result in a microflora disorder, or the subject has been exposed to radiation resulting in a disturbance of the normal microflora, for example in the event of an accident at a nuclear power plant, accident elimination operations, accidental exposure to a damaging radiation, or treatment, such as proton, photon therapy, or exposure to other type of radiation. In this case, if there is no possibility to collect samples of the normal microflora of the subject, a method of treatment using the microflora of a donor selected from the relatives of the subject, for example, relatives on the maternal side, including mother, the mother's sisters and other relatives on the maternal side, may be chosen.

(62) According to one of the embodiments, the method for recovering the composition of the body microflora that has been impaired or weakened by diseases and/or conditions associated with and/or accompanied by a disorder or lack of the subject's own microflora, comprises the following: collection of the microflora of the donor selected from the relatives on the maternal side of the subject; preparation of a solution containing microorganisms isolated from the microflora of a relative of the subject on the maternal side, including bacteria isolated from microflora, and/or bacteria together with bacteriophages isolated from microflora and/or only isolated bacteriophages isolated from microflora; administration of an effective amount of the solution prepared over a period of time sufficient to restore normal microflora to the subject, as described above.

(63) In one of the embodiments, a method for recovery of the subject's microflora is proposed which includes a planned exposure of the subject's microflora to reduce or destroy a pathogenic microflora, followed by recovery of the microflora using a microflora obtained from a healthy donor on the maternal side.

(64) According to one of the embodiments, the method for recovering the composition of the body microflora that has been impaired or weakened by diseases and/or conditions associated with and/or accompanied by a disorder or lack of the subject's own microflora, comprises the following: implementation of an impact on the subject causing the disorder, weakening or destruction of hi s/her microflora; collection of the microflora of the donor selected from the relatives on the maternal side of the subject; preparation of a solution containing microorganisms isolated from the microflora of a relative of the subject on the maternal side, including bacteria isolated from microflora, and/or bacteria together with bacteriophages isolated from microflora and/or only isolated bacteriophages isolated from microflora; administration of an effective amount of the solution prepared over a period of time sufficient to restore normal microflora to the subject, as described above.

(65) According to one of the embodiments, a method for stimulating the immune system of an organism that has been impaired or weakened by diseases and/or conditions associated with and/or accompanied by a disorder or lack of the subject's own microflora is provided, comprising administering the solution or a pharmaceutical dosage form according to any of the described aspects.

(66) According to another aspect of the invention, a method is provided intended for recovery of the microflora composition and increasing the life span of the subject by administering microorganisms obtained from the genuine microflora of the subject or that of his/her relatives on the maternal side at a young age, including bacteria obtained from the microflora and/or bacteria together with bacteriophages, obtained from the microflora, and/or only isolated bacteriophages obtained from the microflora.

(67) According to another aspect of the invention, a method is provided intended for reducing increased intestinal permeability and/or correcting the syndrome of increased intestinal permeability by administering microorganisms obtained prior to induction of increased intestinal permeability from the genuine microflora of the subject or that of his/her relatives on the maternal side, including bacteria obtained from the microflora and/or bacteria together with bacteriophages, obtained from the microflora, and/or only isolated bacteriophages obtained from the microflora.

(68) The invention is illustrated by the following examples, which do not limit the scope of the present invention, but are intended merely to explain possible ways of implementing the invention, which will be apparent to those skilled in the art upon reading this description.

EXAMPLES

Example 1

(69) Inheritance of the Microbiota Nucleus on the Maternal Side

(70) To determine the transfer of the microbiota nucleus on the maternal side, the authors conducted a comparative study of the composition of the microflora of the members of the family chosen for the study and determined the degree of its similarity. Family structure: Mother, 29 Father, 31 Son, 3 Daughter, 2

(71) The DNA was isolated from the samples using DNASorb B kit (InterLabService, Russia). Amplification was carried out using universal bacterial primers flanking the V1-V3 region of the 16S rRNA gene—9F and 541R. Metagenomic sequencing of the fragment of the 16S rRNA gene was carried out on a Roche-454 Genome Sequencer FLX Ti pyrosequencer.

(72) As a result of the study, 53492 readings were obtained, which means that the average coverage was 53492/4 samples=13373 readings.

(73) To assess the similarity of the microbiotic profile (Table 1), UniFrac analysis was used. At that, only the types of microorganisms represented in all members of the family were taken into account to evaluate the results of the study, that is, those microorganisms that form the core of the microflora.

(74) TABLE-US-00001 TABLE 1 Similarity of microflora composition between family members, based on UniFrac analysis Pair for comparison Similarity indicators Mother/son 0.376499 Mother/daughter 0.452154 Father/son 0.405796 Father/daughter 0.525158 Mother/father 0.291984 Son/daughter 0.225282

(75) As can be seen from the presented table, the greatest similarity (smaller discrepancy) is found in the pairs “Mother/Son”, “Mother/daughter” as compared to “Father/Son” and “Father/daughter”, respectively.

(76) Thus, the data obtained show that the microflora of children is inherited mostly from their mother.

Example 2

(77) The Microbiota Nucleus in Samples of Microflora of Various Localization

(78) To confirm the fact that the microorganisms forming the core of the microflora are present in the microflora of various locations, the prevalence of different types of bacteria in the saliva, on the skin and in the feces of the same person was estimated.

(79) The DNA was isolated from the samples (obtained from the mother, see Example 1) using a DNASorb B kit (InterLabService, Russia). Amplification was carried out using universal bacterial primers 27F-534R flanking the hypervariable region of the 16S rRNA gene.

(80) 27F: ‘5-AGAGTTTGATYMTGGCTCAG-3’ (SEQ ID NO: 1)

(81) 534R: ‘5-ATTACCGCGGCTGCTGG-3’ (SEQ ID NO: 2)

(82) Metagenomic sequencing of the fragment of the 16S rRNA gene was carried out on a Roche-454 Genome Sequencer FLX Ti pyrosequencer.

(83) As a result of the experiment, it was established that the examined samples of saliva, skin, and feces contain representatives of the same taxa of microorganisms, in particular:

(84) Actinomycetales

(85) Bacteroidales

(86) Flavobacteriales

(87) Bacillales

(88) Lactobacillales

(89) Clostridiales

(90) Erysipelotrichales

(91) Selenomonadales

(92) Fusobacteriales

(93) Neisseriales

(94) Campylobacterales

(95) Pasteurellales

(96) Thus, it has been established that the “core” of the microflora in the saliva, skin and feces of the same person is represented by bacteria of the same taxa.

(97) According to the data available to the authors, representatives of Archaea are likewise represented in the microbiota.

Example 3

(98) Development of a Pathological Process Under the Effect of Bacteriophages that Are Not Part of the Subject's Own Microflora

(99) The experiment was carried out on rats weighing 200 g which consumed enterally with water a complex of bacteriophages selectively acting on the bacteria of the genera Staphylococcus, Streptococcus, Proteus, Pseudomonas, Salmonella, and types E. coli and K. pneumonia, not part of the subject's own microflora, for 10 days. After 10 days of admission, no changes in the functions of the gastrointestinal tract and, in particular, changes in the nature of defecation were recorded in the animals. Simultaneously, after the third day, the animals showed a deterioration in the condition, which manifested itself in a change in the condition of the fur, a decrease in weight, and a general inhibition. After the termination of reception of foreign bacteriophages, the animals were found to have permeability of the intestinal wall, which was detected by an estimation of the change in the ratio of lactulose:mannitol in urine.

(100) The authors used the change in the “lactulose:mannitol” ratio to assess whether unrelated phages cause microflora diseases manifested by the host organism presumably due to the increased intestinal permeability. For this purpose, the changes in urinary excretion of mannitol, lactulose and the lactulose:mannitol ratio in each animal prior to the study and on the 10th day after the use of foreign phages were compared.

(101) On the 10th day, the animals showed a slight (statistically not significant) decrease in mannitol excretion. At the same time, an increase in excretion of lactulose and a sharp increase in the ratio of lactulose:mannitol were registered, which indicates an increase in intestinal permeability (see Table 2).

(102) TABLE-US-00002 TABLE 2 Mannitol (pmol) Lactulose (pmol) The 10th day after The 10th day after Prior to treatment with Prior to treatment with Experimental beginning of foreign beginning of foreign animal No. the experiment bacteriophages the experiment bacteriophages 1 185 173 66 123 2 164 168 85 193 3 170 162 82 199 4 211 205 61 166 5 157 148 41 133 Average value 177.4 +/− 21.4 171.2 +/− 21.0 67 +/− 17.7 162.8 +/− 34.3

(103) Conclusion from the results of the experiment: The data obtained indicate that oral administration of bacteriophages that are not part of the subject's own microflora can lead to an increase in intestinal permeability, that is, to deterioration of the body condition.

Example 4

(104) Cultivation of the Genuine Microflora Under Conditions that Allow for Growth of the Bacteria Belonging to the Yet Nonculturable

(105) Material from the donor was inoculated on a rich nutrient medium. Any suitable nutrient medium can be used as such a nutrient medium. Before inoculation, the material was diluted with sterile water or an isotonic solution of sodium chloride. The samples were incubated at 37° C. The presence of growth (by clouding of the agar mirror), the evaluation of the quantity and quality of various bacteria was carried out after 48 hours of growth. The vast majority of bacteria on the medium grew into mixed communities, similar to individual colonies. As a part of mixed communities, the majority was still nonculturable bacteria, which cannot be cultivated on a nutrient media.

(106) Material from the donor and the conjunction of bacteria cultivated on a rich nutrient medium that provides the growth of the maximum possible number of different foreign microorganisms have been investigated in metagenomic analysis.

(107) As a result of pyrosequencing, a significant species diversity of bacteria was found in sputum, in which 7 microorganisms, 8 series, and 15 species were detected. These microorganisms gave rise on the rich medium used, which indicates its high efficiency for the cultivation of microbes that occur in the donor material.

(108) In the donor's material, when using the test system, the number of sequences was dominated by microorganisms of 2 orders: Pseudomonadales and Burkholderiales. The representation of Pseudomonadales and Burkholderiales in the donor material was 88.3% and 8.5%, and in the test system—76.5% and 1.0%, respectively. The data obtained is summarized in Table 3.

(109) TABLE-US-00003 TABLE 3 Classi- Pathological Rich nutrient fication material (sputum) medium Order Bacillales Bacillales Pseudomonadales Pseudomonadales Clostridiales Clostridiales Actinomycetales Actinomycetales Lactobacillales Lactobacillales Burkholderiales Burkholderiales Sphingomonadales Sphingomonadales Series Staphylococcaceae Staphylococcaceae Corynebacteriaceae Corynebacteriaceae Streptococcaceae Streptococcaceae Pseudomonadaceae Pseudomonadaceae Alcaligenaceae Alcaligenaceae Carnobacteriaceae Carnobacteriaceae Sphingomonadaceae Sphingomonadaceae Oxalobacteraceae Oxalobacteraceae Species Staphylococcus epidermidis Staphylococcus epidermidis Lactobacillus rhamnosus Lactobacillus rhamnosus Pseudomonas sp Pseudomonas sp Pseudomonas aeruginosa Pseudomonas aeruginosa Achromobacter insolitus Achromobacter insolitus Achromobacter xylosoxidans Achromobacter xylosoxidans Achromobacter sp Achromobacter sp Granulicatella adiacens Granulicatella adiacens Sphingomonas sp Sphingomonas sp Streptococcus sp Streptococcus sp Herbaspirillum sp Herbaspirillum sp Corynebacterium striatum Corynebacterium striatum Granulicatella adiacens Granulicatella adiacens Achromobacter denitrificans Achromobacter denitrificans

(110) As a result of the conducted studies, almost 100% coincidence of microorganism species giving growth on a rich nutrient medium was established, in comparison with species in the donor material. The data obtained indicate that the representation of the bacteria cultivated in such manner from the donor material corresponds to the maximum extent to the original composition of the microbiota, and therefore the bacteria thus cultivated can be used for inclusion into a medicament for reconstitution or creation of the microflora.

Example 5

(111) Preparation of the Solution

(112) To prepare the preparation, freshly collected saliva was used in a volume of 5-10 ml, into which flushing from a cotton swab that is used to collect microbes from the buccal mucosa was added. The washing from the swabs was carried out with 1.0 ml of a sterile isotonic sodium chloride solution. As a result, the maximum variety of oral bacteria, which includes cultured and yet nonculturable microbes was obtained. The obtained material was placed in conical tubes, after which rapid precipitation by centrifugation was carried out. To the resulting precipitate, an isotonic sodium chloride solution was added and individual doses comprising 0.001 to 10.0 ml of the original microbial mixture were prepared.

(113) The resulting mixture was stored under various conditions: at a temperature of −70° C., the liquid nitrogen temperature or in the form of a lyophilized dried preparation. Upon freezing, glycerol was added to the mixture as a stabilizer. The samples were stored frozen in separate vials for later use.

Example 6

(114) Restoration of the Normal Microflora After Irradiation

(115) To evaluate the rate of recovery of the microbiota after its damage caused by irradiation, an animal model was used, using bacteria from the microflora of animals that had not been affected as a therapeutic agent.

(116) For this purpose, sexually mature non-linear rats weighing 180-200 grams were used (Rappolpovo nursery, Leningrad region). The animals were kept in pairs until the appearance of offspring. After the age of the offspring reached 4 months, the animals were admitted in the experiment as recipients of the microflora.

(117) Damage to the microflora in rats was caused by combined radiation (18 Gray, day −3) and using a combination of antibiotics: tetracycline, metronidazole 3 days before the start of the experiment (days −3, −2 and −1). On day 0, the animals received an isolated microbial mixture isolated from feces, once (as described in J. Vaahtovuo et al. Quantification of bacteria in human feces using 16S rRNA-hybridization, DNA-staining and flow cytometry. Journal of Microbiological Methods, Volume 63, Issue 3, December 2005, Pages 276-286.)

(118) The animals were divided into 5 groups:

(119) Group 1. Recipients of the microflora, which received bacteria of their own microflora, isolated before treatment.

(120) Group 2. Recipients of the microflora, which received the bacteria of the microflora of their own mother.

(121) Group 3. Recipients of the microflora, which received the bacteria of the microflora of their own father.

(122) Group 4. Recipients of the microflora, which received the bacteria of the microflora of unrelated rats.

(123) Group 5. Animals with bacterial infection of microflora, which received as treatment the appropriate volume of the solvent used to prepare the drug (the control group).

(124) The composition of the microflora in the recipients was determined, as described in the previous examples, at the following points in time: before the study, on day 0 (day −3 after damaging the microflora, but before the treatment), 2-4-8-12 weeks after the start of treatment. The degree of microflora recovery was estimated as a percentage of the restoration of the diversity of the phylotypes (expressed in the OTU—operational taxonomic unit) of the microorganisms found in feces.

(125) The results are shown in Table 4

(126) TABLE-US-00004 TABLE 4 Degree of microflora recovery (OTU, %) before the start of 2 4 8 12 Group the study day 0 weeks weeks weeks weeks 1 100 26 +/− 3 78 +/− 8 85 +/− 7 93 +/− 3 95 +/− 6 2 100 26 +/− 3 65 +/− 5 79 +/− 6 87 +/− 4 91 +/− 4 3 100 26 +/− 3 43 +/− 4 53 +/− 4 62 +/− 3 75 +/− 6 4 100 26 +/− 3 39 +/− 5 49 +/− 6 56 +/− 5 68 +/− 5 5 100 26 +/− 3 29 +/− 4 34 +/− 4 43 +/− 5 55 +/− 4

(127) Thus, the use of representatives of the microbiota of the genuine microflora obtained before the impact on the body of the subject, or representatives of the mother's microbiota can effectively and quickly restore the composition of microflora after the negative impact on the body of the subject leading to impairment or destruction of the subject's own microflora.

Example 7

(128) Restoration of the Normal Microflora After Irradiation

(129) In this example, the authors used an experimental model of impairment of the microflora similar to the one used in the previous example, however, both bacteria and bacteriophages isolated from the microflora of the animals used as a therapeutic solution were not exposed to the impairing effects.

(130) Damage to the microflora in rats was caused by combined radiation (18 Gray, day −3) and using a combination of antibiotics: Tetracycline and metronidazole 3 days before the start of the experiment (days −3, −2 and −1). On day 0, the animals received bacteria and bacteriophages isolated from feces from the debris, once (as described in J. Vaahtovuo et al. Quantification of bacteria in human feces using 16S rRNA-hybridization, DNA-staining and flow cytometry. Journal of Microbiological Methods, Volume 63, Issue 3, December 2005, Pages 276-286).

(131) The animals were divided into 5 groups:

(132) Group 1. Recipients of the microflora, which received bacteria and bacteriophages of their own microflora, isolated before treatment.

(133) Group 2. Recipients of the microflora, which received the bacteria and bacteriophages of the microflora of their own mother.

(134) Group 3. Recipients of the microflora, which received representatives of their own microflora, isolated before treatment.

(135) Group 4. Recipients of the microflora, which received representatives of the microflora of their own mother.

(136) Group 5. Animals with bacterial infection of microflora, which received as treatment the appropriate volume of the solvent used to prepare the drug (the control group).

(137) The composition of the microflora in the recipients was determined, as described in the previous examples: before the study, on day 0 (day −3 after damaging the microflora, but before the treatment), 2-4-8-12 weeks after the start of treatment. The degree of microflora recovery was estimated as a percentage of the restoration of the diversity of the phylotypes (expressed in the OTU—operational taxonomic unit) of the microorganisms found in feces.

(138) The results are shown in Table 5

(139) TABLE-US-00005 TABLE 5 Degree of microflora recovery (%) before the start of 12 Group the study day 0 2 weeks 4 weeks 8 weeks weeks 1 100 22 +/− 3 86 +/− 8 96 +/− 5 95 +/− 3 95 +/− 4 2 100 22 +/− 3 77 +/− 6 92 +/− 4 93 +/− 5 94 +/− 3 3 100 22 +/− 3 76 +/− 6 83 +/− 6 92 +/− 7 94 +/− 6 4 100 22 +/− 3 68 +/− 4 77 +/− 5 88 +/− 6 92 +/− 5 5 100 22 +/− 3 29 +/− 4 34 +/− 4 43 +/− 5 55 +/− 4

(140) Thus, the use of representatives of the microbiota in conjunction with bacteriophages of the genuine microflora obtained before the impact on the body of the subject, or bacteria and bacteriophages of the mother's microbiota can effectively and quickly restore the composition of microflora after the negative impact on the body of the subject.

Example 8

(141) Restoration of the Normal Microflora After its Damage

(142) To evaluate the possibility of restoring the microbiota after its damage, an animal model was used, using bacteriophages from the microflora of the animals as a therapeutic agent, before the formation of the pathological process, or other animals of this brood that were not affected, related on the maternal side.

(143) Damage to microflora in rats was caused by a combination of ampicillin and metronidazole 3 days before the start of the experiment (days −3, −2 and −1). Clinically, the damage to microflora was assessed by the development of the state of dysbiosis, manifested as antibiotic-associated diarrhea, which developed in 20% of the animals by day 0.

(144) On day 0, the animals received (once) bacteriophages obtained from maternally related animals or isolated from the animal prior to damage of the microflora after removing the debris from the faeces, as described in J. Vaahtovuo et al. Quantification of bacteria in human feces using 16S rRNA-hybridization, DNA-staining and flow cytometry. Journal of Microbiological Methods, Volume 63, Issue 3, December 2005, pages 276-286. Some animals were administered a combination of bacteria and bacteriophages according to the same procedure.

(145) The animals were divided into 5 groups:

(146) Group 1. Recipients of the microflora, which received bacteriophages of their own microflora, isolated before treatment.

(147) Group 2. Recipients of the microflora, which received bacteriophages of the microflora of their own mother.

(148) Group 3. Recipients of the microflora, which received bacteria and bacteriophages of their own microflora, isolated before treatment.

(149) Group 4. Recipients of the microflora, which received representatives of the microbiota of their own mother and bacteriophages of their mother's microflora.

(150) Group 5. Recipients of the microflora, which received representatives of microbiota of their own microflora, isolated before treatment, without bacteriophages.

(151) Group 6. Animals with bacterial infection of microflora, which received as treatment the appropriate volume of the solvent used to prepare the drug (the control group).

(152) The degree of recovery of microflora was assessed by the number of animals in which the symptoms of dysbacteriosis disappeared and in which defecation normalized.

(153) The results are shown in Table 6.

(154) TABLE-US-00006 TABLE 6 Number of animals in the group/number of animals with symptoms of dysbiosis Group day 0 day 3 day 5 day 7 1 8/8 8/2 8/0 8/0 2 8/8 8/2 8/0 8/0 3 8/8 8/2 8/0 8/0 4 8/8 8/2 8/0 8/0 5 8/8 8/4 8/2 8/0 6 8/8 8/8 8/7 8/6

(155) Thus, the use of representatives of bacteriophages obtained from the genuine microflora before the impact on the body of the subject, or bacteriophages obtained from their mother's microflora can effectively and quickly restore the composition of microflora after the negative impact. The use of bacteriophages in conjunction with the microbiota is more effective than the use of bacteria alone.

Example 9

(156) Influence of the Mother's Microflora on the Restoration of Microflora of the Offspring Delivered by Caesarean Section

(157) To assess the influence of the mother's microflora on the restoration of microflora of the offspring delivered by Caesarean section, a model with white non-linear rats was used. It is known that offspring delivered by Caesarean section show a slow increase in weight in comparison with the offspring born naturally. For this purpose, pregnancy of some of the rats of the test group was resolved by Caesarean section, under anesthesia, in accordance with the declaration of the Guide for the Care and Use of Laboratory (Institute of Laboratory Animal Resources (US). Committee on Care, Use of Laboratory Animals, & National Institutes of Health (US). Division of Research Resources. (1985). Guide for the care and use of laboratory animals. National Academies.).

(158) Progeny from each female was divided into the following groups:

(159) Experimental group—received a mixture of bacteria and phages, previously isolated from the mother's feces in the form of drops on a daily basis.

(160) Control group—received only their mother's milk.

(161) The dynamics of weight gain was estimated in % of the norm on days 7 and 14 after delivery (Table 7).

(162) TABLE-US-00007 TABLE 7 Weight gain in % of the norm Group day 7 day 14 Experimental group 78 +/− 5  75 +/− 6 Control group 96 +/− 4 102 +/− 5

(163) It was established that administration of bacteria and bacteriophages from the mother's microflora to the animals delivered by cesarean section leads to normalization of the weight gain in the animals.

Example 10

(164) Assessment of the Possibility of Additional Cultivation of Microbiota Representatives After Storage for Enrichment of the Preparation.

(165) Using rich nutrient media, microorganisms were cultivated that included bacteria isolated from the genuine microbiota. Any nutrient medium suitable for cultivation of microorganisms can be used as a nutrient medium. A comparative metagenomic study was carried out with a qualitative determination of representation of the microorganism in the initial material and cultivated on the nutrient medium used. The possibility of preserving the representation of the microorganisms after prolonged storage (12 months at −70° C.) was also evaluated.

(166) Isolation of DNA from pathological material and bacteria cultivated on the medium was carried out using a standard set of “Sorb-B DNA” (Russia) according to the available protocol. Amplification was carried out using eubacterial primers 27F-534R flanking the hypervariable region of the 16S rRNA gene.

(167) 27F: ‘5-AGAGTTTGATYMTGGCTCAG-3’ (SEQ ID NO: 3)

(168) 534R: ‘5-ATTACCGCGGCTGCTGG-3’ (SEQ ID NO: 4)

(169) Metagenomic sequencing of the fragment of the 16S rRNA gene was carried out on a Roche/454 Genome Sequencer FLX Titanium pyrosequencer. Each sequence obtained during pyrosequencing was identified by comparison with the sequences of GenBank and EzTaxon databases using the BLASTN search algorithms and by pairwise comparison.

(170) For identification, the following similarity thresholds were used (x=similarity): species (x>97%), genera (97>x≥94%), series (94>x≥90%), orders (90>x≥85%), classes (85>x≥80%), fillets (80>x≥75%). To determine the species diversity, taxonomic composition and comparison of communities, Pyrosequencing pipeline software program (http://pyro.cme.msu.edu) was used. The resulting sequences were aligned and cluster analysis was carried out using the Complete Linkage Clustering program, which is part of Pyrosequencing pipeline. Classification of species at all stages of the work is based on the genotypic approach in accordance with the international code of the nomenclature of bacteria (ICNB). In case the representative sequence had homology with the validated microorganism sequence of over 97%, the cluster was assigned to the corresponding species.

(171) As a result of pyrosequencing, a significant species diversity of microorganisms was found in saliva, in the composition of which 7 microorganisms, 8 series, and 15 species were detected. The same microorganisms gave rise to the nutrient medium developed by the authors, which indicates its high efficiency for ensuring the growth of the whole variety of microbes.

(172) TABLE-US-00008 TABLE 8 Microorganisms Microorganisms cultivated on a nutrient Microbiota derived from cultivated medium after saliva on a nutrient medium 12 months of storage Actinomycetaceae Actinomycetaceae Actinomycetaceae Micrococcaceae Micrococcaceae Micrococcaceae Coriobacteriaceae Coriobacteriaceae Coriobacteriaceae Porphyromonadaceae Porphyromonadaceae Porphyromonadaceae Prevotellaceae Prevotellaceae Prevotellaceae Flavobacteriaceae Flavobacteriaceae Flavobacteriaceae Bacillales Bacillales Bacillales Carnobacteriaceae Carnobacteriaceae Carnobacteriaceae Streptococcaceae Streptococcaceae Streptococcaceae Eubacteriaceae Eubacteriaceae Eubacteriaceae Lachnospiraceae Lachnospiraceae Lachnospiraceae Peptostreptococcaceae Peptostreptococcaceae Peptostreptococcaceae Ruminococcaceae Ruminococcaceae Ruminococcaceae Erysipelotrichaceae Erysipelotrichaceae Erysipelotrichaceae Veillonellaceae Veillonellaceae Veillonellaceae Fusobacteriaceae Fusobacteriaceae Fusobacteriaceae Leptotrichiaceae Leptotrichiaceae Leptotrichiaceae Burkholderiaceae Burkholderiaceae Burkholderiaceae Neisseriaceae Neisseriaceae Neisseriaceae Campylobacteraceae Campylobacteraceae Campylobacteraceae Pasteurellaceae Pasteurellaceae Pasteurellaceae Pseudomonadaceae Pseudomonadaceae Pseudomonadaceae Bacillaceae Bacillaceae Bacillaceae Aerococcaceae Aerococcaceae Aerococcaceae Clostridiales Clostridiales Clostridiales

(173) As a result of the conducted studies, 100% coincidence of the types of microorganisms that give growth on the developed nutrient medium was established, both immediately after collection of the material, and after 12 months of storage.

Example 11

(174) Life Span Assessment

(175) The change in the life span of experimental animals was evaluated, while both bacteria with bacteriophages and bacteriophages obtained from the microflora of the same animals, or previously obtained from relatives on the maternal side at a young age, were used as a therapeutic solution.

(176) Starting from the 10.sup.th months of age, the animals received bacteria and bacteriophages isolated from feces after removing of debris, once (as described in J. Vaahtovuo et al. Quantification of bacteria in human feces using 16S rRNA-hybridization, DNA-staining and flow cytometry. Journal of Microbiological Methods, Volume 63, Issue 3, December 2005, Pages 276-286.

(177) The animals (white non-linear mice) were divided into 5 groups:

(178) Group 1. Recipients of the microflora, which received bacteria and bacteriophages isolated from their own microflora at a young age.

(179) Group 2. Recipients of the microflora, which received bacteria and bacteriophages isolated from their own mother's microflora at a young age.

(180) Group 3. Recipients of the microflora, which received bacteriophages isolated from their own microflora at a young age.

(181) Group 4. Recipients of the microflora, which received bacteriophages isolated from their own mother's microflora at a young age.

(182) Group 5. Animals, which received as treatment the appropriate volume of the solvent used to prepare the solution (the control group).

(183) The results are shown in Table 9.

(184) TABLE-US-00009 TABLE 9 Group Increase in life expectancy 1 +38% 2 +26% 3 +28% 4 +21% 5 0%

(185) Thus, the use of microorganisms isolated from the genuine microbiota or microflora of relatives on the maternal side, together with bacteriophages obtained from their own microflora or microflora of relatives on the maternal side, and also the use of only isolated bacteriophages obtained at a young age from the animal itself or from its relatives on the maternal side, allows to effectively and quickly restore the composition of microflora after a negative impact, which, in turn, contributes to an increase in life expectancy, as can be seen from the data shown in Table 9.

Example 12

(186) Evaluation of Correction of Increased Intestinal Permeability

(187) The possibility of correcting the increase in intestinal permeability was evaluated; while both bacteria with bacteriophages and bacteriophages previously obtained from the microflora of the same animals, or obtained from relatives on the maternal side at a young age, were used as a therapeutic solution. Increased intestinal permeability, or the “leaky gut syndrome” syndrome, is associated with development of a significant number of pathologies: Crohn's disease, irritable bowel syndrome, rheumatoid arthritis, Alzheimer's disease, Parkinson's disease, schizophrenia, depression, autism, bipolar disorder, arrhythmias, cachexia, sudden death syndrome, renal and hepatic insufficiency, glomerulonephritis and others.

(188) To simulate the increase in intestinal permeability, winstar rats were given 4 ml of 40% ethanol at a rate of 2 g/kg/day. This dose was progressively increased in such a way that by the 14th day the animals received 8 g/kg/day of 40% ethanol. After 30 days, the animals were divided into 5 groups:

(189) Group 1. Recipients of the microflora, which received bacteria and bacteriophages of their own microflora, isolated before alcohol administration.

(190) Group 2. Recipients of the microflora, which received bacteria and bacteriophages of their own mother's microflora, isolated before alcohol administration.

(191) Group 3. Recipients of the microflora, which received bacteriophages of their own microflora, isolated before alcohol administration.

(192) Group 4. Recipients of the microflora, which received bacteriophages of their own mother's microflora, isolated before alcohol administration.

(193) Group 5. Animals, which received as treatment the appropriate volume of the solvent used to prepare the solution (the control group).

(194) Group 6. Animals of the same brood that did not receive ethanol (with a constant intestinal permeability rate).

(195) After 10 days of treatment, changes in intestinal permeability were determined in animals based on a lactulose/mannitol test.

(196) The results are shown in Table 10.

(197) TABLE-US-00010 TABLE 10 Lactulose/mannitol Lactulose/ ratio on the first mannitol ratio day of testing on day 30 after Lactulose/mannitol ratio before the alcohol the alcohol 10 days after the start of Group administration administration treatment 1 0.27 ± 0.05 1.28 ± 0.07 0.35 ± 0.08 2 0.42 ± 0.02 0.94 ± 0.06 0.48 ± 0.05 3 0.31 ± 0.03 1.02 ± 0.03 0.39 ± 0.04 4 0.43 ± 0.06 0.96 ± 0.08 0.51 ± 0.07 5 0.29 ± 0.05 1.19 ± 0.22 1.23 ± 0.05 6 0.30 ± 0.04 0.90 ± 0.07 0.26 ± 0.05

(198) Thus, the use of microbiota in conjunction with the bacteriophages of the genuine microflora or the microflora of relatives on the maternal side, as well as only isolated bacteriophages obtained before induction of an increase in the gut permeability, in the animal itself or in its relatives on the maternal side, allows for effective and quick correction of leaky gut syndrome and restoration of intestinal permeability.

Example 13

(199) Preventing Development of Tumor Processes

(200) The possibility of preventing the appearance of a tumor process in experimental animals using the solution of the present invention was evaluated, with both bacteria with bacteriophages and bacteriophages previously obtained from the microflora of the same animals, or obtained from relatives on the maternal side at a young age, used as a therapeutic solution.

(201) Starting at week 8, azoxymethane was injected intraperitoneally at the rate of 10 mg/kg once in a week for 6 weeks, in order to induce carcinogenesis, as described in Fukutake M et al. Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2, on azoxymethane-induced colon carcinogenesis in mice. Carcinogenesis, Volume 19, Issue 3, 1998, Pages 1939-1942.

(202) Starting from day 1 of azoxymethane administration, the animals received as a therapeutic solution both bacteria with bacteriophages and bacteriophages previously obtained from the microflora of the same animals, or obtained from their relatives on the maternal side at a young age.

(203) The animals (white non-linear mice) were divided into 5 groups:

(204) Group 1. Recipients of the microflora, which received bacteria and bacteriophages isolated from their own microflora at a young age.

(205) Group 2. Recipients of the microflora, which received bacteria and bacteriophages isolated from their own mother's microflora at a young age.

(206) Group 3. Recipients of the microflora, which received bacteriophages isolated from their own microflora at a young age.

(207) Group 4. Recipients of the microflora, which received bacteriophages isolated from their own mother's microflora at a young age.

(208) Group 5. Animals, which received as treatment the appropriate volume of the solvent used to prepare the solution (the control group).

(209) The results are shown in Table 11.

(210) TABLE-US-00011 TABLE 11 Number of mice with developed intestinal carcinoma/ Group total number of animals in the group (%) 1 0/10 (0%)  2 2/10 (20%) 3 3/10 (30%) 4 3/10 (30%) 5 6/10 (60%)

(211) Thus, from the data given in Table 11, it can be seen that the use of microorganisms isolated from the genuine microbiota or microflora of relatives on the maternal side, together with bacteriophages obtained from their own microflora or microflora of relatives on the maternal side, and also the use of only isolated bacteriophages obtained at a young age from the animal itself or from its relatives on the maternal side, allows to reduce the likelihood of carcinogenesis development.

Example 14

(212) Treatment of Tumor Processes

(213) The change in the development of a tumor process in experimental animals using the solution of the present invention was evaluated, with both bacteria with bacteriophages and bacteriophages previously obtained from the microflora of the same animals, or obtained from relatives on the maternal side at a young age, used as a therapeutic solution.

(214) Starting at week 8, azoxymethane was injected intraperitoneally at the rate of 10 mg/kg once in a week for 6 weeks, in order to induce carcinogenesis, as described in Fukutake M et al. Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2, on azoxymethane-induced colon carcinogenesis in mice. Carcinogenesis, Volume 19, Issue 3, 1998, Pages 1939-1942.

(215) Seven days after the completion of azoxymethane administration, with positive tumor induction were selected and for the following 4 weeks the animals received both bacteria with bacteriophages and bacteriophages previously obtained from the microflora of the same animals, or obtained from their relatives on the maternal side at a young age, as a therapeutic agent. The change in tumor size progression was assessed.

(216) The animals (white non-linear mice) were divided into 5 groups:

(217) Group 1. Recipients of the microflora, which received bacteria and bacteriophages isolated from their own microflora at a young age.

(218) Group 2. Recipients of the microflora, which received bacteria and bacteriophages isolated from their own mother's microflora at a young age.

(219) Group 3. Recipients of the microflora, which received bacteriophages isolated from their own microflora at a young age.

(220) Group 4. Recipients of the microflora, which received bacteriophages isolated from their own mother's microflora at a young age.

(221) Group 5. Animals, which received as treatment the appropriate volume of the solvent used to prepare the solution (the control group).

(222) The results are shown in Table 12.

(223) TABLE-US-00012 TABLE 12 Tumor size after 4 Tumor size before weeks of treatment Group treatment (mm.sup.3) (mm.sup.3) (% change) 1 22.4 ± 4.5 23.5 ± 5.2 (+4.9%)  2 22.4 ± 4.5 25.7 ± 6.3 (+14%)   3 22.4 ± 4.5 28.5 ± 6.8 (+27.2%) 4 22.4 ± 4.5 30.4 ± 7.1 (+35.7%) 5 22.4 ± 4.5 160.3 ± 28.7 (+715%)  

(224) Thus, from the data given in Table 12, it can be seen that the use of microorganisms isolated from the genuine microbiota or microflora of relatives on the maternal side, together with bacteriophages obtained from the genuine microflora or microflora of relatives on the maternal side, and also the use of only isolated bacteriophages obtained at a young age from the animal itself or from its relatives on the maternal side, allows to inhibit carcinogenesis development.

(225) The present application describes a number of examples and embodiments of the invention. Nevertheless, it must be borne in mind that various modifications of the described examples and embodiments can be developed, while not departing from the scope and the essence of the invention in principle. With this in mind, other embodiments are included in the scope of the items listed below. At that, all the numerical ranges described herein include all the sub ranges contained therein, as well as any individual values within the scope of these ranges. All publications, patents and patent applications mentioned in this description are hereby incorporated by reference.